Innovative Medicines Development

Innovative Medicines Development (IMD) was a specialty pharmaceutical company focused on the development of treatments for addiction and drug overdose. The company is most notable for its collaboration with the National Institute on Drug Abuse (NIDA) to develop Narcan (naloxone hydrochloride) Nasal Spray, the first FDA-approved needle-free formulation of naloxone for the emergency treatment of opioid overdose. IMD's business model centered on identifying and advancing high-impact therapies for substance use disorders through strategic partnerships and clinical development. In 2016, the company was acquired by Opiant Pharmaceuticals (formerly Lightlake Therapeutics), which subsequently integrated IMD's assets and expertise into its broader addiction medicine portfolio.